Analysis reports significant survival rates in children treated for relapsed and refractory lymphoma, suggesting brentuximab vedotin enhances outcomes.
Key Points
The 10-year overall survival rate was 76%, indicating effective treatment strategies for relapsed and refractory classical Hodgkin lymphoma.
Inclusion of brentuximab vedotin resulted in a higher relapse-free survival rate of 83%, emphasizing its potential role in therapy.
Seventy-three patients aged 5.5 to 18.6 years were included in this study, providing insights into treatment effectiveness across a pediatric population.
This cooperative effort between two Russian clinics demonstrates the importance of targeted therapies and stem cell transplantation in improving patient outcomes.